Immuno-anticancer agents are active in early lung cancer. Following 'Opdivo (Nivolumab),' which obtained the indication for adjuvant therapy before surgery for the first time, 'Keytruda (Pembrolizumab)' is also seeking to expand its scope as adjuvant therapy before and after surgery.

The data shown by immuno-anticancer drugs in early lung cancer were surprising. When chemotherapy and CCRT were used, 'pCR', which was seen in 1 or 2 out of 100 patients, increased more than 10 times. In the case of Opdivo, a pCR of 24% was recorded in CheckMate-816 phase 3, significantly improving the 2.2% of the chemotherapy alone group. At 3 years, EFS was 57%, exceeding the control group's 43%. Keytruda also had an eve